BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35609821)

  • 1. Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients.
    Liu J; Ma Y; Han P; Wang J; Liu YG; Shi RF; Li J
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101957. PubMed ID: 35609821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
    Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
    Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population.
    Hu R; Wu B; Wang C; Wu Z; Zhang X; Chen X; Lu G; Yuan K
    Int J Surg; 2024 Apr; 110(4):2044-2054. PubMed ID: 38215263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease.
    Shen F; Zheng RD; Shi JP; Mi YQ; Chen GF; Hu X; Liu YG; Wang XY; Pan Q; Chen GY; Chen JN; Xu L; Zhang RN; Xu LM; Fan JG
    Liver Int; 2015 Nov; 35(11):2392-400. PubMed ID: 25689614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled attenuation parameter value-based diagnostic algorithm improves the accuracy of liver stiffness measurement in chronic hepatitis B patients.
    Fan Y; Wang L; Ding Y; Sheng Q; Zhang C; Li Y; Han C; Dou X
    Aging (Albany NY); 2020 Aug; 12(16):16072-16082. PubMed ID: 32836216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation.
    Duarte-Rojo A; Heimbach JK; Borja-Cacho D; Barone GW; Shaheen MF; Lamps LW; Graham RP; Tan EK; Concepcion W; Kim WR
    Transplantation; 2022 Feb; 106(2):318-327. PubMed ID: 33675319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B.
    Goyal R; Mallick SR; Mahanta M; Kedia S; Shalimar ; Dhingra R; Sharma H; Das P; Datta Gupta S; Panda S; Acharya SK
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1738-45. PubMed ID: 23808910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.
    Siddiqui MS; Idowu MO; Stromberg K; Sima A; Lee E; Patel S; Ghaus S; Driscoll C; Sterling RK; John B; Bhati CS
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):367-374. PubMed ID: 32272251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
    Lee JI; Lee HW; Lee KS
    World J Gastroenterol; 2019 Sep; 25(33):4959-4969. PubMed ID: 31543686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus.
    Yu H; Liu H; Zhang J; Jia G; Yang L; Zhang Q; Li G; Liu F; Di F; Wang F
    Ann Palliat Med; 2021 Sep; 10(9):9702-9714. PubMed ID: 34628896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
    Cai YJ; Dong JJ; Wang XD; Huang SS; Chen RC; Chen Y; Wang YQ; Song M; Chen YP; Li Z; Zhou MT; Shi KQ
    J Viral Hepat; 2017 Nov; 24(11):1005-1015. PubMed ID: 28419755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
    Wan T; Köhn N; Kröll D; Berzigotti A
    Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How intrahepatic cholestasis affects liver stiffness in patients with chronic hepatitis B: a study of 1197 patients with liver biopsy.
    Guo H; Liao M; Jin J; Zeng J; Li S; Schroeder DR; Zheng J; Zheng R; Chen S
    Eur Radiol; 2020 Feb; 30(2):1096-1104. PubMed ID: 31673836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound and FibroScan
    Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
    Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Qu Y; Song YY; Chen CW; Fu QC; Shi JP; Xu Y; Xie Q; Yang YF; Zhou YJ; Li LP; Xu MY; Cai XB; Zhang QD; Yu H; Fan JG; Lu LG
    Clin Transl Gastroenterol; 2021 Apr; 12(4):e00323. PubMed ID: 33848277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
    Avcu A; Kaya E; Yilmaz Y
    Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B.
    Wong SW; Chan WK; Mohamed R
    J Viral Hepat; 2020 Dec; 27(12):1297-1305. PubMed ID: 32668489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.